NEW YORK – Quanterix said after the close of the market on Monday that it has entered into a licensing and supply agreement with Siemens Healthineers to provide that company access to neurofilament-light (Nf-L) antibodies.
Siemens will use the technology to develop blood-based Nf-L clinical tests. Financial and other terms of the deal were not disclosed.
Quanterix acquired the technology as part of its $22.5 million acquisition of UmanDiagnostics during the summer. Billerica, Massachusetts-based Quanterix said in a statement that the deal allows it to "supply researchers globally with the 'best-in-class' Simoa Nf-L assay while continuing to innovate new digital biomarkers to advance the field of research in diagnostics for neurological disorders."
The Nf-L biomarker has demonstrated utility in the diagnosis, prognosis, and monitoring of a wide range of conditions, including Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, traumatic brain injury, ALS, Huntington’s disease, and others, Quanterix said when it announced its buy of UmanDiagnostics.
"We believe this will give our researchers even more confidence working with Simoa in research, while leveraging Siemens Healthineers' global footprint to allow Quanterix to share meaningfully in the large IVD market for blood-based neurology testing," Quanterix President, CEO, and Chairman Kevin Hrusovsky said in a statement.